RATIONALE: Testing for minimal residual disease in cell samples from patients with acute lymphoblastic leukemia may help doctors plan better treatment. PURPOSE: This research trial studies a genetic test in identifying previously undetectable minimal residual disease in cell samples from younger patients with acute lymphoblastic leukemia.
OBJECTIVES: * To identify and characterize changes in clonal populations of B cells in children with acute lymphoblastic leukemia (ALL) at diagnosis and Day 29 of induction. * To define the ability of this technology to reclassify patients as minimal residual disease (MRD) positive at Day 29 of induction. * To determine whether more sensitive detection of MRD at Day 29 would have clinical prognostic value in children with ALL. OUTLINE: DNA extracted from diagnostic cells are analyzed for immunoglobulin heavy chain variable region by next-generation sequencing.
Study Type
OBSERVATIONAL
Enrollment
12
Identification and characterization of changes in clonal populations of B cells in children with ALL
Reclassification of patients as MRD positive at day 29
Higher sensitivity detection that allow the stratification of the MRD population into 2 groups with lower and higher likelihood of relapse
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.